[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"fda-warning-letters-search:[\"Cellestis Inc\",\"\",\"\",\"\",\"\",1]":3,"fda-latest-sync-dates":79},{"warningLetters":4,"total":78},[5,33,54],{"id":6,"raw":7,"subject":12,"body_html":15,"body_text":16,"firm_name":17,"letter_id":18,"created_at":19,"fei_number":20,"letter_url":21,"updated_at":22,"action_type":23,"case_status":24,"posted_date":25,"marcs_cms_no":26,"product_type":27,"closeout_date":28,"issuing_office":11,"recipient_name":29,"body_fetched_at":30,"delivery_method":31,"recipient_title":20,"reference_number":20,"action_taken_date":32,"medical_device_id":20,"response_letter_date":20},3052,[8,9,10,11,12,13,14,13],"\u003Ctime datetime=\"2021-11-02T13:20:00Z\">11\u002F02\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-10-20T04:00:00Z\">10\u002F20\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fcellera-llc-618209-10202021\">CellEra LLC\u003C\u002Fa>","Office of Medical Device and Radiological Health Division 1 – East","CGMP\u002FQSR\u002FMedical Devices\u002FAdulterated","","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fcellera-llc-618209-07212022\">\u003Ctime datetime=\"2022-07-25T04:00:00Z\">07\u002F25\u002F2022\u003C\u002Ftime>\n\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>United Parcel Service\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Richard E. Moon\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chief Financial Officer\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>CellEra LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1045 Reed Dr, Ste C\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Monroe\u003C\u002Fspan>, \u003Cspan>OH\u003C\u002Fspan> \u003Cspan>45050\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Office of Medical Device and Radiological Health Division 1 – East\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003Cbr>\nCMS # 618209\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>October 20, 2021\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Moon:\u003C\u002Fp>\n\n\u003Cp>The United States Food and Drug Administration (FDA) conducted an inspection of your firm’s medical device operations at CellEra LLC, located at 1045 Reed Dr, Ste C, Monroe, OH 45050, from June 16 through July 8, 2021. During the inspection, FDA investigators determined that your firm is a specification developer and own label distributor of various sterile wound dressings with drug. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\u003C\u002Fp>\n\n\u003Cp>This inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. We received a response, dated July 30, 2021 from Ken Heyl, Chief Product Officer, concerning our investigators’ observations noted on the Form FDA 483, List of Inspectional Observations (FDA 483) that was issued on July 8, 2021. We address the response below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. Failure to establish and maintain procedures for implementing corrective and preventive actions and the failure to document corrective and preventive activities, as required by 21 CFR § 820.100.\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, your firm does not have a written corrective and preventive action procedure and has failed to document your firm’s corrective actions.\u003C\u002Fp>\n\n\u003Cp>For example, your firm made changes to your Instructions for Use (IFUs) of your sterile Vitále Silver Calcium Alginate wound dressing as a correction to the findings in the previous inspection ending 05\u002F31\u002F2019. However, your firm failed to implement this change and IFUs reviewed during the current inspection still include the following, which are claims not cleared in \u003Cstrong>(b)(4)\u003C\u002Fstrong>:\u003C\u002Fp>\n\n\u003Cp>• The term “antimicrobial” was not changed to “antibacterial”\u003Cbr>\n• The statement “The silver-impregnated calcium alginate fibers, when in contact with wound exudate or blood, form a gel which creates a moist wound healing environment. The silver has an antimicrobial effect within the dressing upon various types of microorganisms including Staphylococcus Aureus and Escherichia Coli”.\u003Cbr>\n• The description of “Superficial or Deep” for wound-type.\u003Cbr>\n• The instruction “cleanse the wound with Vitále Cleanser Spray or physiological saline solution.”\u003C\u002Fp>\n\n\u003Cp>None of your firm’s corrective action activities, including a report of corrective and removal (Z-2085-2019 \u002F RES# 83281) that was reported to the Agency, were documented.\u003C\u002Fp>\n\n\u003Cp>This is a repeated issue from the FORM FDA 483 issued on May 30, 2019 and discussed during the January 14, 2020 Regulatory Meeting.\u003C\u002Fp>\n\n\u003Cp>We reviewed your firm’s response and conclude it is not adequate. Your response did not address the creation of a procedure for CAPA activities or your plan to document corrective and preventive actions.\u003C\u002Fp>\n\n\u003Cp>Further, you provided an updated IFU for the Vitále Silver Calcium Alginate Dressings via email on July 30, 2021. However, you have not provided objective evidence that this new IFU has been approved, the date when the IFU will be included with Vitále Silver Calcium Alginate Dressings, your plan to address the devices currently on the market or ready for distribution that contain an IFU with language beyond what was originally cleared by the Agency under \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Further, your response did not address initiating a CAPA(s) for the above IFU changes.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>2. Failure to establish and maintain procedures to control the design of the device, as required by 21 CFR § 820.30.\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, your firm has failed to establish design controls that include adequate procedures for design inputs, design outputs, design verifications, design validations, design reviews, design transfers, design changes and the establishment of a design history file.\u003C\u002Fp>\n\n\u003Cp>This is a repeated issue from the FORM FDA 483 issued on May 30, 2019 and discussed during the January 14, 2020 Regulatory Meeting.\u003C\u002Fp>\n\n\u003Cp>We reviewed your firm’s response and conclude it is not adequate. You do not address the establishment of procedures to control the design of devices developed by your firm. In your response, please provide your firm’s plan to address the lack of design control procedures and establishment of a design history file.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>3. Failure to establish and maintain procedures for the identification, documentation, validation or where appropriate verification, review, and approval of design changes before their implementation, as required by 21 CFR § 820.30(i).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, your firm indicated to our investigator that an estimated \u003Cstrong>(b)(4)\u003C\u002Fstrong> design changes have been made by your firm in the past \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Some of these design changes include changes to the IFUs for the Vitále Silver Calcium Alginate Dressings beyond the language cleared under \u003Cstrong>(b)(4)\u003C\u002Fstrong>, the storage requirements for the Vitále Silver Calcium Alginate Dressings from \"Keep from Heat\" “below 77°F” to “41°F \u002F 5°C – 104°F \u002F 40°C”, a change to the sterilization method from \u003Cstrong>(b)(4)\u003C\u002Fstrong> to \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and a change to the shelf life of the Vitále Silver Calcium Alginate Ropes &amp; Dressings from 2 years to 3 years. These design changes have been made without documentation to include validation, verification, review, and approval prior to implementation.\u003C\u002Fp>\n\n\u003Cp>This is a repeated issue from the FORM FDA 483 issued on May 30, 2019 and discussed during the January 14, 2020 Regulatory Meeting.\u003C\u002Fp>\n\n\u003Cp>We have reviewed your firm’s response and conclude it is not adequate. Your response indicated that you have drafted a form to use to make changes in products. Your response is not adequate because the “Product Change Request\u002FApproval” form does not include the requirement or allow for documentation of validation, verification (where appropriate), or review of the design change prior to approval. Additionally, you did not provide a retrospective review of design changes your firm has conducted to ensure design change requirements have been met.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>4. Failure to establish and maintain procedures to ensure that all purchased or otherwise received product and services conform to specified requirements as required by 21 CFR § 820.50.\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, your firm failed to develop purchasing control procedures and has not established and maintained the requirements, including quality requirements, that must be met by suppliers, contractors, and consultants.\u003C\u002Fp>\n\n\u003Cp>For example, your firm utilizes \u003Cstrong>(b)(4)\u003C\u002Fstrong> contract manufacturers to manufacture the products distributed by your firm. There is no agreement(s) in place that the contract manufacturers agree to notify your firm of changes in the product so your firm can determine whether the changes may affect the quality of a finished device. The storage requirements, sterilization method, and shelf life were changed by the contract manufacturer of your Vitále Silver Calcium Alginate Ropes &amp; Dressings without your firm’s knowledge or approval.\u003C\u002Fp>\n\n\u003Cp>This is a repeated issue from the FORM FDA 483 issued on May 30, 2019 and discussed during the January 14, 2020 Regulatory Meeting.\u003C\u002Fp>\n\n\u003Cp>We have reviewed your firm’s response and conclude it is not adequate. Your response indicated that a procedure would be provided by September 8, 2021. To date, a procedure has not been received. Further, your response does not mention how your firm intends to define the type and extent of control to be exercised over contract manufacturers of your products from making changes or if you intend to create an agreement to be notified of changes in products.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>5. Failure to establish and maintain procedures for acceptance of incoming product. Incoming product shall be inspected, tested, or otherwise verified as conforming to specified requirements as required by 21 CFR § 820.80(b).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, your firm failed to develop procedures for acceptance of incoming product nor does your firm perform any activities related to the acceptance of incoming product other than a visual inspection for noticeable damage to the shipping boxes and device cartons. For example, you stated that sterility certificates received from your contract manufacturers are simply filed and not reviewed.\u003C\u002Fp>\n\n\u003Cp>This is a repeated issue from the FORM FDA 483 issued on May 30, 2019 and discussed during the January 14, 2020 Regulatory Meeting.\u003C\u002Fp>\n\n\u003Cp>We have reviewed your firm’s response and conclude it is not adequate. Your response indicated that a procedure would be provided by September 8, 2021. To date, a procedure has not been received.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>6. Failure to establish and maintain procedures for receiving, reviewing, and evaluating complaints by a formally designated unit as required by 21 CFR § 820.198.\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, your firm failed to developed procedures for the receipt, review, and evaluation of complaints. For example, your firm receives oral complaints, but no record is made. Complaints received via your firm’s website are maintained in email format without any indication of evaluation by your firm.\u003C\u002Fp>\n\n\u003Cp>This is a repeated issue from the FORM FDA 483 issued on May 30, 2019 and discussed during the January 14, 2020 Regulatory Meeting.\u003C\u002Fp>\n\n\u003Cp>We have reviewed your firm’s response and conclude it is not adequate. Your response indicated that your plan to have a formally designated unit to handle complaints and a procedure to follow. This response also indicated that no procedure finish date has been established. To date, a procedure or anticipated date of completion have not been received.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>7. Failure to establish and maintain procedures to control all documents as required by 21 CFR § 820.40.\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>We have reviewed your firm’s response and conclude it is not adequate. Your response did not address the corrective actions you plan to take. It is unclear if your firm plans to create a document control procedure.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>8. Failure to establish and maintain procedures to adequately control environmental conditions, where environmental conditions could reasonably be expected to have an adverse effect on product quality. Environmental control system(s) shall be periodically inspected to verify that the system, including necessary equipment, is adequate and functioning properly. These activities shall be documented and reviewed as required by 21 CFR § 820.70(c).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, your firm’s Vitále Silver Calcium Alginate Dressings and Ropes, which are sterile medical devices, have specific temperature storage requirements. Your firm has not developed procedures to adequately control the environmental conditions needed to maintain the environmental requirements, to including storage temperatures, for your devices.\u003C\u002Fp>\n\n\u003Cp>This is a repeated issue from the FORM FDA 483 issued on May 30, 2019 and discussed during the January 14, 2020 Regulatory Meeting.\u003C\u002Fp>\n\n\u003Cp>We have reviewed your firm’s response and conclude it is not adequate. Your response indicated that you plan to draft a procedure with a deadline of January 31, 2022. In your response, please provide an explanation why this procedure will take until January 31, 2022 to be established. Additionally, please explain how your firm intends to verify that the \u003Cstrong>(b)(4)\u003C\u002Fstrong> temperature and humidity sensors currently in use at your firm are adequate and functioning properly.\u003C\u002Fp>\n\n\u003Cp>Our inspection also revealed that your Vitále Silver Calcium Alginate Dressings and Ropes are misbranded under Section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information regarding the device that is required by or under Section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 803 – Medical Device Reporting. Violation includes, but is not limited to:\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>9. Failure to develop, maintain, and implement written Medical Device Reporting (MDR) procedures, as required by 21 CFR 803.17.\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, your firm has not established procedures for timely and effective identification, communication, and evaluation of reportable events; a standardized review process for determining when an event meets reportability criteria; timely submission of MDRs to the FDA; or for compliance with the applicable documentation and recordkeeping requirements.\u003C\u002Fp>\n\n\u003Cp>We have reviewed your firm’s response and conclude it is not adequate. In the response, your firm noted you plan to develop these procedures but have not established a date to develop the procedure.\u003C\u002Fp>\n\n\u003Cp>Your firm should take prompt action to correct the violations addressed in this letter. Failure to promptly correct these violations may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties. Also, federal agencies may be advised of the issuance of Warning Letters about devices so that they may take this information into account when considering the award of contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been corrected. Also, should FDA determine that your devices do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted. If you believe that your products are not in violation of the Act, please respond to FDA with your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to correct the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned\u003Cbr>\ncorrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address all violations included in this Warning Letter.\u003C\u002Fp>\n\n\u003Cp>If you have questions regarding any issues in this letter, please contact Compliance Officer, Sean Moynihan at 410-779-5134 or at sean.moynihan@fda.hhs.gov. Please send your reply electronically to Gina Brackett, Director of Compliance Branch, at oradevices1firmresponse@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of the violations and take prompt actions to correct the violations and bring the products into compliance.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Arduino Frankovic\u003Cbr>\nActing Program Division Director\u003Cbr>\nOffice of Medical Device and Radiological Health\u003Cbr>\nDivision 1 – East\u003C\u002Fp>\n\n\u003Cp>Cc:\u003C\u002Fp>\n\n\u003Cp>Ken Heyl\u003Cbr>\nChief Product Officer\u003Cbr>\n2044 Grove Park Way\u003Cbr>\nBirmingham, AL 35242\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nUnited Parcel Service\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nRichard E. Moon\n\nRecipient Title\n\nChief Financial Officer\n\nCellEra LLC\n\n1045 Reed Dr, Ste C\n\nMonroe, OH 45050\n\nUnited States\n\nIssuing Office:\n\nOffice of Medical Device and Radiological Health Division 1 – East\n\nUnited States\n\nWARNING LETTER\n\nCMS # 618209\n\nOctober 20, 2021\n\nDear Mr. Moon:\n\nThe United States Food and Drug Administration (FDA) conducted an inspection of your firm’s medical device operations at CellEra LLC, located at 1045 Reed Dr, Ste C, Monroe, OH 45050, from June 16 through July 8, 2021. During the inspection, FDA investigators determined that your firm is a specification developer and own label distributor of various sterile wound dressings with drug. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\n\nThis inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. We received a response, dated July 30, 2021 from Ken Heyl, Chief Product Officer, concerning our investigators’ observations noted on the Form FDA 483, List of Inspectional Observations (FDA 483) that was issued on July 8, 2021. We address the response below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\n\n1. Failure to establish and maintain procedures for implementing corrective and preventive actions and the failure to document corrective and preventive activities, as required by 21 CFR § 820.100.\n\nSpecifically, your firm does not have a written corrective and preventive action procedure and has failed to document your firm’s corrective actions.\n\nFor example, your firm made changes to your Instructions for Use (IFUs) of your sterile Vitále Silver Calcium Alginate wound dressing as a correction to the findings in the previous inspection ending 05\u002F31\u002F2019. However, your firm failed to implement this change and IFUs reviewed during the current inspection still include the following, which are claims not cleared in (b)(4):\n\n• The term “antimicrobial” was not changed to “antibacterial”\n\n• The statement “The silver-impregnated calcium alginate fibers, when in contact with wound exudate or blood, form a gel which creates a moist wound healing environment. The silver has an antimicrobial effect within the dressing upon various types of microorganisms including Staphylococcus Aureus and Escherichia Coli”.\n\n• The description of “Superficial or Deep” for wound-type.\n\n• The instruction “cleanse the wound with Vitále Cleanser Spray or physiological saline solution.”\n\nNone of your firm’s corrective action activities, including a report of corrective and removal (Z-2085-2019 \u002F RES# 83281) that was reported to the Agency, were documented.\n\nThis is a repeated issue from the FORM FDA 483 issued on May 30, 2019 and discussed during the January 14, 2020 Regulatory Meeting.\n\nWe reviewed your firm’s response and conclude it is not adequate. Your response did not address the creation of a procedure for CAPA activities or your plan to document corrective and preventive actions.\n\nFurther, you provided an updated IFU for the Vitále Silver Calcium Alginate Dressings via email on July 30, 2021. However, you have not provided objective evidence that this new IFU has been approved, the date when the IFU will be included with Vitále Silver Calcium Alginate Dressings, your plan to address the devices currently on the market or ready for distribution that contain an IFU with language beyond what was originally cleared by the Agency under (b)(4). Further, your response did not address initiating a CAPA(s) for the above IFU changes.\n\n2. Failure to establish and maintain procedures to control the design of the device, as required by 21 CFR § 820.30.\n\nSpecifically, your firm has failed to establish design controls that include adequate procedures for design inputs, design outputs, design verifications, design validations, design reviews, design transfers, design changes and the establishment of a design history file.\n\nThis is a repeated issue from the FORM FDA 483 issued on May 30, 2019 and discussed during the January 14, 2020 Regulatory Meeting.\n\nWe reviewed your firm’s response and conclude it is not adequate. You do not address the establishment of procedures to control the design of devices developed by your firm. In your response, please provide your firm’s plan to address the lack of design control procedures and establishment of a design history file.\n\n3. Failure to establish and maintain procedures for the identification, documentation, validation or where appropriate verification, review, and approval of design changes before their implementation, as required by 21 CFR § 820.30(i).\n\nSpecifically, your firm indicated to our investigator that an estimated (b)(4) design changes have been made by your firm in the past (b)(4). Some of these design changes include changes to the IFUs for the Vitále Silver Calcium Alginate Dressings beyond the language cleared under (b)(4), the storage requirements for the Vitále Silver Calcium Alginate Dressings from \"Keep from Heat\" “below 77°F” to “41°F \u002F 5°C – 104°F \u002F 40°C”, a change to the sterilization method from (b)(4) to (b)(4), and a change to the shelf life of the Vitále Silver Calcium Alginate Ropes & Dressings from 2 years to 3 years. These design changes have been made without documentation to include validation, verification, review, and approval prior to implementation.\n\nThis is a repeated issue from the FORM FDA 483 issued on May 30, 2019 and discussed during the January 14, 2020 Regulatory Meeting.\n\nWe have reviewed your firm’s response and conclude it is not adequate. Your response indicated that you have drafted a form to use to make changes in products. Your response is not adequate because the “Product Change Request\u002FApproval” form does not include the requirement or allow for documentation of validation, verification (where appropriate), or review of the design change prior to approval. Additionally, you did not provide a retrospective review of design changes your firm has conducted to ensure design change requirements have been met.\n\n4. Failure to establish and maintain procedures to ensure that all purchased or otherwise received product and services conform to specified requirements as required by 21 CFR § 820.50.\n\nSpecifically, your firm failed to develop purchasing control procedures and has not established and maintained the requirements, including quality requirements, that must be met by suppliers, contractors, and consultants.\n\nFor example, your firm utilizes (b)(4) contract manufacturers to manufacture the products distributed by your firm. There is no agreement(s) in place that the contract manufacturers agree to notify your firm of changes in the product so your firm can determine whether the changes may affect the quality of a finished device. The storage requirements, sterilization method, and shelf life were changed by the contract manufacturer of your Vitále Silver Calcium Alginate Ropes & Dressings without your firm’s knowledge or approval.\n\nThis is a repeated issue from the FORM FDA 483 issued on May 30, 2019 and discussed during the January 14, 2020 Regulatory Meeting.\n\nWe have reviewed your firm’s response and conclude it is not adequate. Your response indicated that a procedure would be provided by September 8, 2021. To date, a procedure has not been received. Further, your response does not mention how your firm intends to define the type and extent of control to be exercised over contract manufacturers of your products from making changes or if you intend to create an agreement to be notified of changes in products.\n\n5. Failure to establish and maintain procedures for acceptance of incoming product. Incoming product shall be inspected, tested, or otherwise verified as conforming to specified requirements as required by 21 CFR § 820.80(b).\n\nSpecifically, your firm failed to develop procedures for acceptance of incoming product nor does your firm perform any activities related to the acceptance of incoming product other than a visual inspection for noticeable damage to the shipping boxes and device cartons. For example, you stated that sterility certificates received from your contract manufacturers are simply filed and not reviewed.\n\nThis is a repeated issue from the FORM FDA 483 issued on May 30, 2019 and discussed during the January 14, 2020 Regulatory Meeting.\n\nWe have reviewed your firm’s response and conclude it is not adequate. Your response indicated that a procedure would be provided by September 8, 2021. To date, a procedure has not been received.\n\n6. Failure to establish and maintain procedures for receiving, reviewing, and evaluating complaints by a formally designated unit as required by 21 CFR § 820.198.\n\nSpecifically, your firm failed to developed procedures for the receipt, review, and evaluation of complaints. For example, your firm receives oral complaints, but no record is made. Complaints received via your firm’s website are maintained in email format without any indication of evaluation by your firm.\n\nThis is a repeated issue from the FORM FDA 483 issued on May 30, 2019 and discussed during the January 14, 2020 Regulatory Meeting.\n\nWe have reviewed your firm’s response and conclude it is not adequate. Your response indicated that your plan to have a formally designated unit to handle complaints and a procedure to follow. This response also indicated that no procedure finish date has been established. To date, a procedure or anticipated date of completion have not been received.\n\n7. Failure to establish and maintain procedures to control all documents as required by 21 CFR § 820.40.\n\nWe have reviewed your firm’s response and conclude it is not adequate. Your response did not address the corrective actions you plan to take. It is unclear if your firm plans to create a document control procedure.\n\n8. Failure to establish and maintain procedures to adequately control environmental conditions, where environmental conditions could reasonably be expected to have an adverse effect on product quality. Environmental control system(s) shall be periodically inspected to verify that the system, including necessary equipment, is adequate and functioning properly. These activities shall be documented and reviewed as required by 21 CFR § 820.70(c).\n\nSpecifically, your firm’s Vitále Silver Calcium Alginate Dressings and Ropes, which are sterile medical devices, have specific temperature storage requirements. Your firm has not developed procedures to adequately control the environmental conditions needed to maintain the environmental requirements, to including storage temperatures, for your devices.\n\nThis is a repeated issue from the FORM FDA 483 issued on May 30, 2019 and discussed during the January 14, 2020 Regulatory Meeting.\n\nWe have reviewed your firm’s response and conclude it is not adequate. Your response indicated that you plan to draft a procedure with a deadline of January 31, 2022. In your response, please provide an explanation why this procedure will take until January 31, 2022 to be established. Additionally, please explain how your firm intends to verify that the (b)(4) temperature and humidity sensors currently in use at your firm are adequate and functioning properly.\n\nOur inspection also revealed that your Vitále Silver Calcium Alginate Dressings and Ropes are misbranded under Section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information regarding the device that is required by or under Section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 803 – Medical Device Reporting. Violation includes, but is not limited to:\n\n9. Failure to develop, maintain, and implement written Medical Device Reporting (MDR) procedures, as required by 21 CFR 803.17.\n\nSpecifically, your firm has not established procedures for timely and effective identification, communication, and evaluation of reportable events; a standardized review process for determining when an event meets reportability criteria; timely submission of MDRs to the FDA; or for compliance with the applicable documentation and recordkeeping requirements.\n\nWe have reviewed your firm’s response and conclude it is not adequate. In the response, your firm noted you plan to develop these procedures but have not established a date to develop the procedure.\n\nYour firm should take prompt action to correct the violations addressed in this letter. Failure to promptly correct these violations may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties. Also, federal agencies may be advised of the issuance of Warning Letters about devices so that they may take this information into account when considering the award of contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been corrected. Also, should FDA determine that your devices do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted. If you believe that your products are not in violation of the Act, please respond to FDA with your reasoning and any supporting information for our consideration.\n\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to correct the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned\n\ncorrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address all violations included in this Warning Letter.\n\nIf you have questions regarding any issues in this letter, please contact Compliance Officer, Sean Moynihan at 410-779-5134 or at sean.moynihan@fda.hhs.gov. Please send your reply electronically to Gina Brackett, Director of Compliance Branch, at oradevices1firmresponse@fda.hhs.gov.\n\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of the violations and take prompt actions to correct the violations and bring the products into compliance.\n\nSincerely,\n\n\u002FS\u002F\n\nArduino Frankovic\n\nActing Program Division Director\n\nOffice of Medical Device and Radiological Health\n\nDivision 1 – East\n\nCc:\n\nKen Heyl\n\nChief Product Officer\n\n2044 Grove Park Way\n\nBirmingham, AL 35242","CellEra LLC","cellera-llc-618209-10202021","2026-08-18T06:42:29.386127+00:00",null,"https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fcellera-llc-618209-10202021","2026-10-26T08:08:12.54362+00:00","Warning Letter","Closed Out","2021-11-02","618209","Medical Devices","2022-07-25","Richard E. Moon","2026-08-20T02:28:11.249+00:00","United Parcel Service","2021-10-20",{"id":34,"raw":35,"subject":40,"body_html":41,"body_text":42,"firm_name":43,"letter_id":44,"created_at":45,"fei_number":20,"letter_url":46,"updated_at":47,"action_type":23,"case_status":48,"posted_date":49,"marcs_cms_no":50,"product_type":51,"closeout_date":20,"issuing_office":39,"recipient_name":20,"body_fetched_at":52,"delivery_method":20,"recipient_title":20,"reference_number":20,"action_taken_date":53,"medical_device_id":20,"response_letter_date":20},496,[36,37,38,39,40,13,13,13],"\u003Ctime datetime=\"2025-11-05T17:00:00Z\">11\u002F05\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-11-03T05:00:00Z\">11\u002F03\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fcelestapro-718613-11032025\">CelestaPro\u003C\u002Fa>","Center for Drug Evaluation and Research (CDER)","Unapproved New Drugs\u002FMisbranded Botox","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\u003C\u002Fdd>\n                    \n            \u003Cdd>CelestaPro\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n  \u003Cdiv>\n    \u003Cdiv>Secondary Issuing Offices\u003C\u002Fdiv>\n          \u003Cdiv>\n              \u003Cdiv>    \u003Cbr>\n    \n     \n        \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n    \n    \n    \n    \n\u003C\u002Fdiv>\n              \u003C\u002Fdiv>\n      \u003C\u002Fdiv>\n\n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>November 3, 2025\u003C\u002Fp>\u003Cp>CelestaPro:\u003C\u002Fp>\u003Cp>This is to advise you that the United States (U.S.) Food and Drug Administration (FDA) recently reviewed your website at the Internet address www.celestapro.com and has observed that your website introduces into interstate commerce misbranded and unapproved new drugs in violation of sections 301(a), 301(d), 503(b), and 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) [21 U.S.C. §§ 331(a), 331(d), 353(b), and 355(a)]. As discussed below, FDA has observed that www.celestapro.com introduces into interstate commerce unapproved and misbranded injectable botulinum toxin drug products.\u003C\u002Fp>\u003Cp>There are inherent risks to consumers who purchase unapproved new drugs and misbranded drugs. Unapproved new drugs do not carry the same assurances of safety and effectiveness as those drugs subject to FDA oversight. Drugs that have circumvented regulatory safeguards may be contaminated, counterfeit, contain varying amounts of active ingredients, or contain different ingredients altogether. Furthermore, injectable drug products can pose a serious risk of harm to users because they bypass many of the body’s natural defenses against toxic ingredients, toxins, or dangerous organisms that can lead to serious and life-threatening conditions such as septicemia or sepsis. Accordingly, FDA requests that www.celestapro.com cease offering any unapproved and misbranded drugs for sale to U.S. consumers. This is critical to shielding the American public from harm.\u003C\u002Fp>\u003Cp>\u003Cstrong>Unapproved New Drugs:\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Certain products offered for sale by www.celestapro.com are drugs within the meaning of section 201(g) of the FD&amp;C Act [21 U.S.C. § 321(g)] because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease and\u002For because they are intended to affect the structure or function of the body. These drugs are also new drugs as defined by section 201(p) of the FD&amp;C Act [21 U.S.C. § 321(p)], because they are not generally recognized as safe and effective for their labeled uses. With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in section 505(a) of the FD&amp;C Act [21 U.S.C. § 355(a)]. No approved applications pursuant to section 505 of the FD&amp;C Act are in effect for these products. Accordingly, their introduction or delivery for introduction into interstate commerce violates sections 301(d) [21 U.S.C. § 331(d)] and 505(a) of the FD&amp;C Act.\u003C\u002Fp>\u003Cp>An example of an unapproved botulinum toxin drug product you offer for sale on www.celestapro.com is botulinum toxin type A marketed as “Nabota 200 Unit”. Evidence obtained from your website establishing that this product is a drug intended for human use (as defined in 21 CFR 201.128) includes the claim “Hyperhidrosis” under “Application area”.\u003C\u002Fp>\u003Cp>While there are FDA-approved versions of botulinum toxin drug products on the market in the U.S., there are no approved drug applications pursuant to section 505 of the FD&amp;C Act in effect for “Nabota 200 Unit” offered by www.celestapro.com. Currently there are several botulinum toxin products FDA-approved for the U.S. market and these products are only available pursuant to a prescription from a licensed practitioner. Examples of FDA-approved botulinum toxin products with a summary of their indications are: BOTOX® (onabotulinumtoxinA), indicated for the treatment of overactive bladder, neurogenic detrusor overactivity, chronic migraine, spasticity, cervical dystonia, severe primary axillary hyperhidrosis, strabismus, and blepharospasm and prophylaxis of headaches in adults with chronic migraines; DAXXIFY® (daxibotulinumtoxinA-lanm), indicated for the temporary improvement in the appearance of glabellar lines and the treatment of cervical dystonia; and MYOBLOC® (rimabotulinumtoxinB), indicated for the treatment of cervical dystonia and chronic sialorrhea.\u003C\u002Fp>\u003Cp>Furthermore, FDA-approved botulinum toxin drug products bear a boxed warning, commonly referred to as a “black box warning,” which is the strongest warning FDA requires, indicating that the drug carries a significant risk of serious or even life-threatening adverse effects. The boxed warning addresses the risk of distant spread of toxin effect to produce symptoms consistent with botulinum toxin effects. In addition, swallowing and breathing difficulties can be life threatening and there have been reports of death.\u003C\u002Fp>\u003Cp>\u003Cstrong>Misbranded Drugs:\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>A drug is misbranded under section 502(f)(1) of the FD&amp;C Act [21 U.S.C. § 352(f)(1)] if its labeling fails to bear adequate directions for use. “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (see 21 CFR 201.5). Prescription drugs, as defined in section 503(b)(1) of the FD&amp;C Act [21 U.S.C. § 353(b)(1)] include those that, because of their toxicity or other potentiality for harmful effect, and\u002For the method of their use, and\u002For the collateral measures necessary for their use, are not safe for use except under supervision of a practitioner licensed by law to administer them. Prescription drugs, as defined in section 503(b)(1)(A) of the FD&amp;C Act, can be used safely only at the direction, and under the supervision, of a licensed practitioner.\u003C\u002Fp>\u003Cp>Because the aforementioned drug is a prescription drug intended for conditions that are not amenable to self-diagnosis and treatment by a layperson, adequate directions cannot be written such that a layperson can use the products safely for their intended use. Consequently, the labeling for these drug products fail to bear adequate directions for use, causing them to be misbranded under section 502(f)(1) of the FD&amp;C Act. In addition, because these drugs are not approved in the U.S., they are also not exempt under 21 CFR 201.115(a) from the requirements of section 502(f)(1) of the FD&amp;C Act. By offering these drugs for sale to U.S. consumers, www.celestapro.com is causing the introduction of misbranded drugs into interstate commerce in violation of section 301(a) of the FD&amp;C Act [21 U.S.C. § 331(a)].\u003C\u002Fp>\u003Cp>FDA is sending this warning letter to www.celestapro.com because of the inherent risks to consumers who purchase misbranded and unapproved new drugs. This letter is not intended to identify all the ways in which your products or operations might be in violation of the law. It is your responsibility to ensure that all products you offer for sale are in compliance with the FD&amp;C Act and its implementing regulations. You should take prompt action to address any violations of the FD&amp;C Act (which may include the offer for sale of similarly misbranded and\u002For unapproved new drugs other than the drug products noted above). We advise you to review your websites, product labels, and other labeling and promotional materials to ensure that you are not misleadingly representing your products as safe and effective for a use for which they have not been approved by FDA and that you are not distributing misbranded and unapproved drug products in violation of the FD&amp;C Act.\u003C\u002Fp>\u003Cp>Please notify this office in writing within 15 working days describing the specific steps you have taken to address any violations and to prevent their recurrence. Include an explanation of each step being taken to remedy and prevent the recurrence of any violations, as well as copies of related documentation. Failure to adequately address this matter may result in legal action, including, without limitation, seizure, and injunction, without further notice. If you cannot complete corrective action within 15 working days, state the reason for the delay and the time within which you will complete the corrections. This letter notifies you of our concerns and provides you with an opportunity to address them. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration within 15 working days.\u003C\u002Fp>\u003Cp>If you are not located in the U.S., please note that products that appear to be misbranded or unapproved new drugs may be detained or refused admission. We may advise the appropriate regulatory officials in the country from which you operate that your products referenced above appear to be unapproved and misbranded products that cannot be legally sold to consumers in the U.S.\u003C\u002Fp>\u003Cp>Please direct your response and any inquiries to FDA at FDAInternetPharmacyTaskForce-CDER@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003Cbr>Sangeeta Vaswani Chatterjee, Pharm.D.\u003Cbr>Acting Director\u003Cbr>Office of Drug Security, Integrity, and Response\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003Cbr>&nbsp;\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Product:\n\nDrugs\n\nRecipient:\n\nCelestaPro\n\nUnited States\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nSecondary Issuing Offices\n\nUnited States\n\nWARNING LETTER\nNovember 3, 2025\nCelestaPro:\nThis is to advise you that the United States (U.S.) Food and Drug Administration (FDA) recently reviewed your website at the Internet address www.celestapro.com and has observed that your website introduces into interstate commerce misbranded and unapproved new drugs in violation of sections 301(a), 301(d), 503(b), and 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) [21 U.S.C. §§ 331(a), 331(d), 353(b), and 355(a)]. As discussed below, FDA has observed that www.celestapro.com introduces into interstate commerce unapproved and misbranded injectable botulinum toxin drug products.\nThere are inherent risks to consumers who purchase unapproved new drugs and misbranded drugs. Unapproved new drugs do not carry the same assurances of safety and effectiveness as those drugs subject to FDA oversight. Drugs that have circumvented regulatory safeguards may be contaminated, counterfeit, contain varying amounts of active ingredients, or contain different ingredients altogether. Furthermore, injectable drug products can pose a serious risk of harm to users because they bypass many of the body’s natural defenses against toxic ingredients, toxins, or dangerous organisms that can lead to serious and life-threatening conditions such as septicemia or sepsis. Accordingly, FDA requests that www.celestapro.com cease offering any unapproved and misbranded drugs for sale to U.S. consumers. This is critical to shielding the American public from harm.\nUnapproved New Drugs:\nCertain products offered for sale by www.celestapro.com are drugs within the meaning of section 201(g) of the FD&C Act [21 U.S.C. § 321(g)] because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease and\u002For because they are intended to affect the structure or function of the body. These drugs are also new drugs as defined by section 201(p) of the FD&C Act [21 U.S.C. § 321(p)], because they are not generally recognized as safe and effective for their labeled uses. With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in section 505(a) of the FD&C Act [21 U.S.C. § 355(a)]. No approved applications pursuant to section 505 of the FD&C Act are in effect for these products. Accordingly, their introduction or delivery for introduction into interstate commerce violates sections 301(d) [21 U.S.C. § 331(d)] and 505(a) of the FD&C Act.\nAn example of an unapproved botulinum toxin drug product you offer for sale on www.celestapro.com is botulinum toxin type A marketed as “Nabota 200 Unit”. Evidence obtained from your website establishing that this product is a drug intended for human use (as defined in 21 CFR 201.128) includes the claim “Hyperhidrosis” under “Application area”.\nWhile there are FDA-approved versions of botulinum toxin drug products on the market in the U.S., there are no approved drug applications pursuant to section 505 of the FD&C Act in effect for “Nabota 200 Unit” offered by www.celestapro.com. Currently there are several botulinum toxin products FDA-approved for the U.S. market and these products are only available pursuant to a prescription from a licensed practitioner. Examples of FDA-approved botulinum toxin products with a summary of their indications are: BOTOX® (onabotulinumtoxinA), indicated for the treatment of overactive bladder, neurogenic detrusor overactivity, chronic migraine, spasticity, cervical dystonia, severe primary axillary hyperhidrosis, strabismus, and blepharospasm and prophylaxis of headaches in adults with chronic migraines; DAXXIFY® (daxibotulinumtoxinA-lanm), indicated for the temporary improvement in the appearance of glabellar lines and the treatment of cervical dystonia; and MYOBLOC® (rimabotulinumtoxinB), indicated for the treatment of cervical dystonia and chronic sialorrhea.\nFurthermore, FDA-approved botulinum toxin drug products bear a boxed warning, commonly referred to as a “black box warning,” which is the strongest warning FDA requires, indicating that the drug carries a significant risk of serious or even life-threatening adverse effects. The boxed warning addresses the risk of distant spread of toxin effect to produce symptoms consistent with botulinum toxin effects. In addition, swallowing and breathing difficulties can be life threatening and there have been reports of death.\nMisbranded Drugs:\nA drug is misbranded under section 502(f)(1) of the FD&C Act [21 U.S.C. § 352(f)(1)] if its labeling fails to bear adequate directions for use. “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (see 21 CFR 201.5). Prescription drugs, as defined in section 503(b)(1) of the FD&C Act [21 U.S.C. § 353(b)(1)] include those that, because of their toxicity or other potentiality for harmful effect, and\u002For the method of their use, and\u002For the collateral measures necessary for their use, are not safe for use except under supervision of a practitioner licensed by law to administer them. Prescription drugs, as defined in section 503(b)(1)(A) of the FD&C Act, can be used safely only at the direction, and under the supervision, of a licensed practitioner.\nBecause the aforementioned drug is a prescription drug intended for conditions that are not amenable to self-diagnosis and treatment by a layperson, adequate directions cannot be written such that a layperson can use the products safely for their intended use. Consequently, the labeling for these drug products fail to bear adequate directions for use, causing them to be misbranded under section 502(f)(1) of the FD&C Act. In addition, because these drugs are not approved in the U.S., they are also not exempt under 21 CFR 201.115(a) from the requirements of section 502(f)(1) of the FD&C Act. By offering these drugs for sale to U.S. consumers, www.celestapro.com is causing the introduction of misbranded drugs into interstate commerce in violation of section 301(a) of the FD&C Act [21 U.S.C. § 331(a)].\nFDA is sending this warning letter to www.celestapro.com because of the inherent risks to consumers who purchase misbranded and unapproved new drugs. This letter is not intended to identify all the ways in which your products or operations might be in violation of the law. It is your responsibility to ensure that all products you offer for sale are in compliance with the FD&C Act and its implementing regulations. You should take prompt action to address any violations of the FD&C Act (which may include the offer for sale of similarly misbranded and\u002For unapproved new drugs other than the drug products noted above). We advise you to review your websites, product labels, and other labeling and promotional materials to ensure that you are not misleadingly representing your products as safe and effective for a use for which they have not been approved by FDA and that you are not distributing misbranded and unapproved drug products in violation of the FD&C Act.\nPlease notify this office in writing within 15 working days describing the specific steps you have taken to address any violations and to prevent their recurrence. Include an explanation of each step being taken to remedy and prevent the recurrence of any violations, as well as copies of related documentation. Failure to adequately address this matter may result in legal action, including, without limitation, seizure, and injunction, without further notice. If you cannot complete corrective action within 15 working days, state the reason for the delay and the time within which you will complete the corrections. This letter notifies you of our concerns and provides you with an opportunity to address them. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration within 15 working days.\nIf you are not located in the U.S., please note that products that appear to be misbranded or unapproved new drugs may be detained or refused admission. We may advise the appropriate regulatory officials in the country from which you operate that your products referenced above appear to be unapproved and misbranded products that cannot be legally sold to consumers in the U.S.\nPlease direct your response and any inquiries to FDA at FDAInternetPharmacyTaskForce-CDER@fda.hhs.gov.\nSincerely,\n\u002FS\u002F\nSangeeta Vaswani Chatterjee, Pharm.D.\nActing Director\nOffice of Drug Security, Integrity, and Response\nOffice of Compliance\nCenter for Drug Evaluation and Research","CelestaPro","celestapro-718613-11032025","2026-08-18T06:42:28.498414+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fcelestapro-718613-11032025","2026-10-26T08:08:12.469641+00:00","Issued","2025-11-05","718613","Drugs","2026-08-19T16:07:13.676+00:00","2025-11-03",{"id":55,"raw":56,"subject":62,"body_html":63,"body_text":64,"firm_name":65,"letter_id":66,"created_at":67,"fei_number":20,"letter_url":68,"updated_at":69,"action_type":23,"case_status":48,"posted_date":70,"marcs_cms_no":71,"product_type":72,"closeout_date":20,"issuing_office":60,"recipient_name":73,"body_fetched_at":74,"delivery_method":75,"recipient_title":20,"reference_number":76,"action_taken_date":77,"medical_device_id":20,"response_letter_date":20},581,[57,58,59,60,61,13,13,13],"\u003Ctime datetime=\"2025-09-23T04:00:00Z\">09\u002F23\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-09-12T04:00:00Z\">09\u002F12\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fcellebration-llc-713252-09122025\">Cellebration LLC \u003C\u002Fa>","Center for Biologics Evaluation and Research (CBER)","Deviations\u002FCFR\u002FRegulations for Human Cells, Tissues &amp; Cellular Products (HCT\u002FPs)","Deviations\u002FCFR\u002FRegulations for Human Cells, Tissues & Cellular Products (HCT\u002FPs)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS and Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>CBER 25-713252\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Biologics                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>George Kaltner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chief Executive Officer and President \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Cellebration LLC \u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>(b)(6)\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>San Juan\u003C\u002Fspan> \u003Cspan>00909\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Puerto Rico\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:george@cellebration.com\"> george@cellebration.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Biologics Evaluation and Research (CBER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>September 12, 2025\u003C\u002Fp>\u003Cp>\u003Cstrong>CBER 25-713252\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Dear Mr. Kaltner:\u003C\u002Fp>\u003Cp>The United States Food and Drug Administration (FDA) reviewed your company’s website, https:\u002F\u002Fwww.cellebration.com\u002Fconditions (last visited September 2025), through which your company offers cellular products derived from cord blood for use in the treatment or prevention of various diseases or conditions, such as autism, cerebral palsy, chronic pain, colitis, Crohn’s disease, degenerative disease, gout, liver cirrhosis, multiple sclerosis, neurological disorders, Parkinson’s disease, spine and disc conditions, sports injuries, and arthritis. As a result, your products are drugs as defined in section 201(g)(1) of the FD&amp;C Act, 21 U.S.C. § 321(g)(1), and biological products as defined in section 351(i) of the PHS Act, 42 U.S.C. § 262(i).\u003C\u002Fp>\u003Cp>It is a prohibited act under section 301(e) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. § 331(e), to refuse to permit access to or copying of any record as required by section 704(a) of the FD&amp;C Act, 21 U.S.C. § 374(a).\u003C\u002Fp>\u003Cp>Under section 704(a)(4) of the FD&amp;C Act, 21 U.S.C. § 374(a)(4), you are required to provide within a reasonable timeframe, within reasonable limits, and in a reasonable manner, requested records or information that FDA may inspect under section 704. However, your firm failed to comply with this requirement.\u003C\u002Fp>\u003Cp>Specifically, on October 18, 2024, FDA sent an electronic request for records and other information pursuant to section 704(a)(4) of the FD&amp;C Act to the above address. On November 5, 2024, you requested a 30-day extension to the submission deadline. You noted the additional time would allow your firm to “work closely with legal counsel to meet all standards and respond comprehensively.” On November 13, 2024, FDA approved your extension request. On January 3, 2025, your firm requested a second 30-day extension due to the holidays and an unexpected illness. FDA approved this request on January 10, 2025. As you failed to answer our initial request for records, we sent a second request via e-mail on April 23, 2025. You indicated on April 28, 2025, that you had sent your response weeks earlier; however, our records reflect that no such response was received. On May 19, 2025, FDA requested that you resend the response referenced in your email. In response, you stated that you were unclear about what we were seeking. On May 21 and May 28, 2025, we sent additional follow-up emails again asking you to provide the requested records.\u003C\u002Fp>\u003Cp>FDA has not received a response to its request to date even though FDA’s request and follow-up communications sufficiently and clearly described the records sought. Your refusal to permit access to or copying of any record required by section 704(a), 21 U.S.C. § 374(a), violates section 301(e) of the FD&amp;C Act, 21 U.S.C. § 331(e).\u003C\u002Fp>\u003Cp>In response to this letter, we again ask you to provide the information and records requested by FDA pertaining to Cellebration, located at \u003Cstrong>(b)(6)\u003C\u002Fstrong> San Juan, PR, 00909, and your cellular products derived from cord blood.\u003C\u002Fp>\u003Cp>Your firm should take prompt action to address this matter. This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action being initiated by FDA without further notice, including, without limitation, seizure and\u002For injunction.\u003C\u002Fp>\u003Cp>We request that you respond in writing within fifteen (15) working days from your receipt of this letter. If you cannot address this matter within fifteen (15) working days, please explain the reason for your delay and the timeframe for completion. If you do not believe your products are in violation of the FD&amp;C Act, PHS Act, or applicable regulations, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\u003Cp>Send your electronic response and any questions regarding this letter to CBERDCMRecommendations@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Melissa J. Mendoza\u003Cbr>Director\u003Cbr>Office of Compliance and Biologics Quality&nbsp;&nbsp;\u003Cbr>Center for Biologics Evaluation and Research\u003C\u002Fp>\u003Cp>Cc:&nbsp;\u003C\u002Fp>\u003Cp>George Kaltner\u003Cbr>Cellebration Regeneration Limited Liability Company\u003Cbr>15 Ave. Munoz Rivera, Suite 103\u003Cbr>Paseo Caribe, San Juan, PR 00901\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS and Electronic Mail\n\nReference #:\n\nCBER 25-713252\n\nProduct:\n\nBiologics\n\nRecipient:\n\nRecipient Name\n\nGeorge Kaltner\n\nRecipient Title\n\nChief Executive Officer and President\n\nCellebration LLC\n\n(b)(6)\n\nSan Juan 00909\n\nPuerto Rico\n\ngeorge@cellebration.com\n\nIssuing Office:\n\nCenter for Biologics Evaluation and Research (CBER)\n\nUnited States\n\nWARNING LETTER\nSeptember 12, 2025\nCBER 25-713252\nDear Mr. Kaltner:\nThe United States Food and Drug Administration (FDA) reviewed your company’s website, https:\u002F\u002Fwww.cellebration.com\u002Fconditions (last visited September 2025), through which your company offers cellular products derived from cord blood for use in the treatment or prevention of various diseases or conditions, such as autism, cerebral palsy, chronic pain, colitis, Crohn’s disease, degenerative disease, gout, liver cirrhosis, multiple sclerosis, neurological disorders, Parkinson’s disease, spine and disc conditions, sports injuries, and arthritis. As a result, your products are drugs as defined in section 201(g)(1) of the FD&C Act, 21 U.S.C. § 321(g)(1), and biological products as defined in section 351(i) of the PHS Act, 42 U.S.C. § 262(i).\nIt is a prohibited act under section 301(e) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. § 331(e), to refuse to permit access to or copying of any record as required by section 704(a) of the FD&C Act, 21 U.S.C. § 374(a).\nUnder section 704(a)(4) of the FD&C Act, 21 U.S.C. § 374(a)(4), you are required to provide within a reasonable timeframe, within reasonable limits, and in a reasonable manner, requested records or information that FDA may inspect under section 704. However, your firm failed to comply with this requirement.\nSpecifically, on October 18, 2024, FDA sent an electronic request for records and other information pursuant to section 704(a)(4) of the FD&C Act to the above address. On November 5, 2024, you requested a 30-day extension to the submission deadline. You noted the additional time would allow your firm to “work closely with legal counsel to meet all standards and respond comprehensively.” On November 13, 2024, FDA approved your extension request. On January 3, 2025, your firm requested a second 30-day extension due to the holidays and an unexpected illness. FDA approved this request on January 10, 2025. As you failed to answer our initial request for records, we sent a second request via e-mail on April 23, 2025. You indicated on April 28, 2025, that you had sent your response weeks earlier; however, our records reflect that no such response was received. On May 19, 2025, FDA requested that you resend the response referenced in your email. In response, you stated that you were unclear about what we were seeking. On May 21 and May 28, 2025, we sent additional follow-up emails again asking you to provide the requested records.\nFDA has not received a response to its request to date even though FDA’s request and follow-up communications sufficiently and clearly described the records sought. Your refusal to permit access to or copying of any record required by section 704(a), 21 U.S.C. § 374(a), violates section 301(e) of the FD&C Act, 21 U.S.C. § 331(e).\nIn response to this letter, we again ask you to provide the information and records requested by FDA pertaining to Cellebration, located at (b)(6) San Juan, PR, 00909, and your cellular products derived from cord blood.\nYour firm should take prompt action to address this matter. This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action being initiated by FDA without further notice, including, without limitation, seizure and\u002For injunction.\nWe request that you respond in writing within fifteen (15) working days from your receipt of this letter. If you cannot address this matter within fifteen (15) working days, please explain the reason for your delay and the timeframe for completion. If you do not believe your products are in violation of the FD&C Act, PHS Act, or applicable regulations, include your reasoning and any supporting information for our consideration.\nSend your electronic response and any questions regarding this letter to CBERDCMRecommendations@fda.hhs.gov.\nSincerely,\n\u002FS\u002F\nMelissa J. Mendoza\nDirector\nOffice of Compliance and Biologics Quality\nCenter for Biologics Evaluation and Research\nCc:\nGeorge Kaltner\nCellebration Regeneration Limited Liability Company\n15 Ave. Munoz Rivera, Suite 103\nPaseo Caribe, San Juan, PR 00901","Cellebration LLC","cellebration-llc-713252-09122025","2026-08-18T06:42:28.676509+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fcellebration-llc-713252-09122025","2026-10-26T08:08:12.504022+00:00","2025-09-23","713252","Biologics","George Kaltner","2026-08-19T16:17:34.124+00:00","VIA UPS and Electronic Mail","CBER 25-713252","2025-09-12",3,{"510k":80,"classification":81,"enforcement":82,"event":83,"event_backfill":84,"pma":85,"warning_letter":86},"2026-11-16T02:00:55.89+00:00","2026-11-16T02:00:41.999+00:00","2026-11-16T02:00:49.415+00:00","2026-11-17T04:00:34.414+00:00","2026-09-07T05:17:28.839+00:00","2026-11-16T02:01:03.155+00:00","2026-11-17T01:02:55.859+00:00"]